How to prescribe Nurtec ODT[1]

- **NURTEC ODT 75 mg**
- **Once daily PRN for migraine**
- **Dispense #8**

Additional prescribing considerations:[1]

Packaging: Nurtec ODT comes in 8-tablet packs

Once daily PRN: Take one 75 mg orally disintegrating tablet (ODT), as needed, for migraine

24 hour max: one 75 mg ODT

30 day max: The safety of treating more than 15 migraines in a 30-day period has not been established

SAVE

Eligible patients with commercial insurance may **pay as little as $0 per month.*** Learn more at **Nurtec-hcp.com/savings-support**. See footnote on next page.

INDICATION

Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Please see additional Important Safety Information on the next page and click here for full Prescribing Information.

Nurtec™ ODT
(rimegepant)
orally disintegrating tablets 75 mg

*Patients with commercial insurance may be able to pay as little as $0 per month. This offer is invalid for patients without commercial insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DOD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. See full Terms & Conditions at www.Nurtec.com/copay-terms for eligibility and restrictions.

IMPORTANT SAFETY INFORMATION (CONT'D)

Warnings and Precautions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included dyspnea and rash, and can occur days after administration.

Adverse Reactions: The most common adverse reaction was nausea (2% in patients who received Nurtec ODT compared to 0.4% in patients who received placebo). Hypersensitivity, including dyspnea and rash, occurred in less than 1% of patients treated with Nurtec ODT.

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4, strong or moderate inducers of CYP3A or inhibitors of P-gp or BCRP. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4.

Use in Specific Populations: *Pregnant/breast feeding*: It is not known if Nurtec ODT can harm an unborn baby or if it passes into breast milk. *Hepatic impairment*: Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment*: Avoid use in patients with end-stage renal disease.

INDICATION

Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use
Nurtec ODT is not indicated for the preventive treatment of migraine.

Please click here for full Prescribing Information.

Price disclosure information for prescribers available here: Nurtec-HCP.com/pricing

REFERENCE: 1. Nurtec ODT [prescribing information]. New Haven, CT: Biohaven Pharmaceuticals, Inc.

biohaven™ pharmaceuticals

Nurtec™ ODT (rimegepant) orally disintegrating tablets 75 mg

US-RIMODT-2000242 04/20